Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease in children and may lead to cirrhosis requiring liver transplant. Thus, prompt diagnosis of advanced fibrosis is essential. Our objectives were to examine PRO-C3 (a neo-epitope pro-peptide of type III collagen formation) levels across childhood/adolescence and associations with advanced fibrosis in pediatric NAFLD. This cross-sectional study included 88 children and adolescents with biopsy-proven NAFLD (mean age: 13.9 ± 2.9 years, 71% male) and 65 healthy participants (11.8 ± 4.5 years, 38% male). PRO-C3, and the bone remodeling biomarkers C-terminal telopeptide of type I collagen (CTX-I; bone resorption) and osteocalcin (N-MID; bone formation), were measured in serum by enzyme-linked immunosorbent assay. Fibrosis was assessed by liver biopsy in participants with NAFLD, who were categorized as having advanced (Ishak score ≥ 3) or none/mild fibrosis (Ishak score ≤ 2). Overall, PRO-C3 was similar in participants with NAFLD (median [interquartile range]: 20.6 [15.8, 25.9] ng/mL) versus healthy participants (19.0 [13.8, 26.0] ng/mL), but was significantly lower in older adolescents ≥ 15 years old (16.4 [13.0, 21.2] ng/mL) compared with children ≤ 10 years old (22.9 [18.1, 28.4] ng/mL; P < 0.001) or 11-14 years old (22.4 [18.3, 31.2] ng/mL; P < 0.001). PRO-C3 was also directly correlated with levels of CTX-I and N-MID (r = 0.64 and r = 0.62, respectively; both P < 0.001). Among participants with NAFLD, PRO-C3 was higher in those with advanced fibrosis (median [IQR]: 28.5 [21.6, 37.6]) compared with none/mild fibrosis (20.3 [18.2, 22.8]; P = 0.020) in models adjusted for age, sex, and body mass index z-score. However, associations were attenuated after additionally adjusting for bone-remodeling CTX-I (P = 0.09) or N-MID (P = 0.08). Conclusion: Collectively, these findings show that PRO-C3 levels are higher in children with advanced fibrosis in NAFLD, but are also influenced by age and pubertal growth spurt, assessed by bone remodeling biomarkers, and therefore may not be a reliable biomarker for liver fibrosis in pediatric NAFLD until late adolescence. (Hepatology Communications 2021;5:1860-1872).
(hepatic steatosis) and can progress to a more severe form of the disease called nonalcoholic steatohepatitis (NASH), characterized by portal and/or lobular inflammation with hepatocyte injury. A few natural history studies have shown that children with NASH have low-grade chronic tissue inflammation and over time can develop progressive fibrosis and other comorbidities, especially type 2 diabetes, and may eventually require liver transplantation.\(^{(3,4)}\)

This potential progression of NAFLD to fibrosis and cirrhosis in children and young adults is concerning, given evidence that advanced fibrosis may be the most crucial histologic feature in predicting mortality in patients with NAFLD.\(^{(5,6)}\) Liver biopsy historically stands as the gold standard for diagnosing liver fibrosis; however, this is an invasive and expensive procedure prone to sampling error.\(^{(7)}\) Therefore, several fibrosis scoring systems based on routine laboratory and/or clinical measures have been proposed, but none have proven to be as valid in children as in adults.\(^{(8)}\)

Fibrogenesis is based on remodeling characterized by the excess production and deposition of extracellular matrix (ECM). This dynamic process leads to the constant release of proteins related to degradation or formation of ECM.\(^{(9)}\) PRO-C3, a neo-epitope pro-peptide of type III collagen formation, has been shown to be a strong and independent predictor of fibrosis stage in adults with NAFLD.\(^{(10,11)}\) In longitudinal studies in adults, change in PRO-C3 over time has been shown to correlate with histological changes in fibrosis.\(^{(12,13)}\) Furthermore, in recent clinical trials, PRO-C3 has shown promising results as a biomarker to monitor fibrosis response to therapy.\(^{(14-17)}\)

Because of the high prevalence of pediatric NAFLD and risks associated with progression to advanced fibrosis, there is a critical need to develop noninvasive methods for screening, diagnosing, and monitoring fibrosis in children and adolescents with NAFLD. In this study, our objectives were to describe PRO-C3 levels in a cross-sectional sample of children and adolescents with and without NAFLD in relation to age, sex, race/ethnicity, weight status, and the pubertal growth spurt (measured through the surrogate markers of bone turnover C-terminal telopeptide of type I collagen [CTX-I] and osteocalcin [N-MID]),\(^{(18)}\) and examine whether PRO-C3 differs in children with NAFLD and advanced fibrosis compared with NAFLD and none/mild fibrosis or healthy children.

**Patients and Methods**

**STUDY POPULATION**

The initial study consisted of a cohort of 260 children who underwent liver biopsy at Children’s Healthcare of Atlanta from 2006 to 2020 as part of the Emory Liver Biopsy Data Biorepository.\(^{(19,20)}\) Among these, 93 children were eligible for the present study based on having a stored blood sample for analysis and a NAFLD diagnosis by liver biopsy (steatosis > 5%); other etiologies were excluded by standard clinical, laboratory, and pathology assessment. We then excluded 1 participant due to age (> 19 years old), 3 due to insufficient sample quantity, and 1 due to inconclusive fibrosis biopsy score, for a final sample of 88 children with biopsy-proven NAFLD.

As a comparison group, we selected control participants from three completed or ongoing studies at Emory University and Children’s Healthcare of Atlanta. This included (1) 16 healthy participants from an ongoing, cross-sectional, observational study.
of children being evaluated for suspected eosinophilic esophagitis (the EoE study); (2) 16 healthy participants from a previously completed, randomized, controlled fructose challenge trial (baseline samples only) (the Sweet Bev study); and (3) 34 healthy participants from an ongoing, cross-sectional, observational, data biorepository study of environmental exposures and childhood health (the PEACH study). All selected participants had a stored blood sample (at −80°C) available for analysis were 2-18 years old, had no chronic disease based on medical chart review, had alanine aminotransferase (ALT) ≤ 50 U/L for boys and ≤ 44 U/L for girls (two times the upper limit of cutoffs from the SAFETY study), and, if the participant was obese, had recent clinical testing to rule out hepatic steatosis (≤ 5.5% based on magnetic resonance imaging [MRI]). One participant was excluded from the final analysis due to an insufficient sample, for a total of 65 healthy participants. Written informed consent was provided by all participants 18 years or older. For participants < 18 years, parents/guardians provided written informed consent, and participants provided verbal assent (if 6-10 years) or written assent (if 11-17 years). These protocols were approved by the institutional review boards at Emory University (Atlanta, GA) and Children’s Healthcare of Atlanta (Atlanta, GA).

COVARIATE ASSESSMENT

Basic demographics, including age, sex, and race/ethnicity, and anthropometric measurements, including height in centimeters and weight in kilograms, were obtained at the time of liver biopsy and/or by medical chart review. Age and sex-adjusted body mass index (BMI) z-scores and percentiles were calculated using Centers for Disease Control and Prevention 2000 growth charts. Weight category was derived from BMI percentiles, and participants were categorized with overweight if BMI > 85th and obesity if BMI > 95th percentile.

HISTOLOGICAL ASSESSMENT

Liver biopsies were clinically indicated and processed according to the local clinical routine, which included staining with hematoxylin and eosin and Masson’s trichrome. For the purpose of this study, each section was independently and blindly reassessed by expert pathologists. Fibrosis was evaluated using the NASH Clinical Research Network (NASH CRN) staging system (0 = none; 1 = perisinusoidal or periportal; 1A = mild, zone 3, perisinusoidal; 1B = moderate, zone 3, perisinusoidal; 1C = portal/periportal; 2 = perisinusoidal and portal/periportal; 3 = bridging fibrosis; and 4 = cirrhosis). The Ishak staging system (0 = no fibrosis; 1 = fibrous expansion of some portal area; 2 = fibrous expansion of most portal areas; 3 = fibrous expansion of most portal areas with occasional bridging; 4 = fibrous expansion of most portal areas with marked bridging; 5 = marked bridging occasional nodules; and 6 = cirrhosis). For the primary analysis, we used the Ishak staging system to dichotomize participants with NAFLD as with advanced fibrosis (Ishak score ≥ 3) or none/mild fibrosis (Ishak score ≤ 2) due to its seven-tired staging system, which provides a finer distinction of fibrosis changes and structural remodeling than other scoring systems, and allowed us to identify more participants with advanced fibrosis (n = 8). However, we also performed a sensitivity analysis to assess whether results were similar if we dichotomized participants with NAFLD based on NASH CRN fibrosis scores (advanced fibrosis = scores ≥ 3; and none/mild fibrosis = scores ≤ 2). Liver biopsies were also scored based on other histopathological features, including grade of steatosis (0 ≤ 5%; 1 = 5%-33%; 2 = 34%-66%; and 3 ≥ 66%), lobular inflammation (0 = no foci; 1 = two or fewer foci per ×200 field; 2 = two to four foci per ×200 field; and 3 = four or more foci per ×200 field), portal inflammation (0 = none; 1 = mild; and 2 = more than mild), and hepatocyte ballooning (0 = none; 1 = few; and 2 = many).

BIOMARKER QUANTIFICATION

Blood samples were collected before liver biopsy and stored at −80°C until use. Biochemical markers that were assessed were the liver enzymes ALT and aspartate aminotransferase (AST), which were measured by standard methods at the Children’s Healthcare of Atlanta clinical laboratory. A neo-epitope marker specific for the assessment of the ADAMTS-2 (ADAM metallopeptidase with thrombospondin type 1 motif 2)–released N-terminal pro-peptide of type III collagen was assessed in serum samples by the use of PRO-C3, a competitive enzyme-linked immunoassay developed by Nordic Bioscience (Herlev,
Denmark), as previously described. CTX-I and N-MID, surrogate markers of bone turnover, associated with growth spurt in boys and girls, were assessed in serum samples using the Roche Elecsys platform (Basel, Switzerland) at Nordic Bioscience.

STATISTICAL ANALYSIS

Descriptive statistics were performed to assess the characteristics of the sample overall and according to NAFLD group. Continuous variables were assessed for normality using histograms and the Shapiro-Wilk test, and nonparametric variables were reported as medians and interquartile ranges (IQRs). Otherwise, means and SDs were reported for continuous variables, and counts and frequencies were reported for categorical variables. Differences between NAFLD and control participants were assessed by t-tests for parametric variables and Mann-Whitney U test for nonparametric variables and chi-square test for categorical variables. The relationship between PRO-C3 levels in childhood and adolescence with participant characteristics and the bone biomarkers CTX-I and N-MID were examined with Spearman correlation for continuous variables and Kruskal-Wallis one-way analysis of variance for categorical variables. All analyses were performed in the full sample set and stratified by sex and by NAFLD status. Scatter plots were created to visualize trends in PRO-C3 according to categorical participant characteristics using the ggplot2 package in R. Trend lines were created using linear regression (method = “lm”) or nonparametric local regression (method = “loess”). To examine whether PRO-C3 levels differed in participants with advanced fibrosis, we constructed linear regression models with fibrosis stage (advanced fibrosis, none/mild fibrosis, or healthy participants) as the independent variable. Stepwise adjustment for covariates was as follows: Model 1 was adjusted for age, sex, race/ethnicity, and BMI z-score; model 2 was adjusted for model 1 covariates plus CTX-I; and model 3 was adjusted for model 1 covariates and N-MID. Due to skewed distributions, PRO-C3, CTX-I, and N-MID were all log-transformed before analyses. Results are therefore reported as the back-transformed least-squares means (LS-means) and 95% confidence intervals (CIs) for PRO-C3 in each fibrosis group. All statistical analyses were performed using SAS Statistical Software (version 9.4; SAS Institute Inc., Cary, NC), and all figures were created using R statistical software (version 3.4.4; R Foundation for Statistical Computing, Vienna, Austria).

Results

SAMPLE CHARACTERISTICS

The characteristics of the sample overall and according to NAFLD group are summarized in Table 1. Participants with NAFLD, compared with healthy participants, were older (mean ± SD: 13.9 ± 2.9 vs. 12.0 ± 4.4 years, respectively), had a higher mean BMI z-score (3.1 ± 0.6 vs. 0.8 ± 1.1), and a higher percentage of males (72% vs. 39%) and Hispanic race/ethnicity (64% vs. 32%). ALT and AST were also higher in participants with NAFLD (median [IQR]: 90.5 [72.0, 129.2] vs. 18.0 [15.0, 22.0] for ALT and 44.5 [34, 80] vs. 18.5 [16.3, 23.8] for AST, respectively).

TRENDS IN PRO-C3 LEVELS IN CHILDHOOD AND ADOLESCENCE

Medians and IQRs for PRO-C3 according to categorical participant characteristics are given in Table 2. All analyses were performed in the full sample set and stratified by sex and by NAFLD status. Scatter plots were created to visualize trends in PRO-C3 according to categorical participant characteristics using the ggplot2 package in R. Trend lines were created using linear regression (method = “lm”) or nonparametric local regression (method = “loess”). To examine whether PRO-C3 levels differed in participants with advanced fibrosis, we constructed linear regression models with fibrosis stage (advanced fibrosis, none/mild fibrosis, or healthy participants) as the independent variable. Stepwise adjustment for covariates was as follows: Model 1 was adjusted for age, sex, race/ethnicity, and BMI z-score; model 2 was adjusted for model 1 covariates plus CTX-I; and model 3 was adjusted for model 1 covariates and N-MID. Due to skewed distributions, PRO-C3, CTX-I, and N-MID were all log-transformed before analyses. Results are therefore reported as the back-transformed least-squares means (LS-means) and 95% confidence intervals (CIs) for PRO-C3 in each fibrosis group. All statistical analyses were performed using SAS Statistical Software (version 9.4; SAS Institute Inc., Cary, NC), and all figures were created using R statistical software (version 3.4.4; R Foundation for Statistical Computing, Vienna, Austria).
pro-C3 levels according to fibrosis stage among children with and without NAFLD

We next examined whether pro-C3 levels differed in children with NAFLD and advanced fibrosis (Ishak score ≥ 3) compared to children with NAFLD and none/mild fibrosis (Ishak score < 3) and healthy children. The characteristics of the sample according to fibrosis status are given in Table 3. Compared to participants with none/mild fibrosis, those with advanced fibrosis had a higher percentage of boys (75% vs. 71.2%) and Hispanic race/ethnicity (87.5% vs. 61.2%), and were younger (mean ± SD: 11.4 ± 2.2 years vs. 14.2 ± 2.9 years). ALT was also higher in advanced fibrosis (median [IQR]: 188 [93.2, 316]) versus none/mild fibrosis (89.5 [68, 122.2]) (Table 3). In unadjusted analyses, pro-C3 levels differed significantly by fibrosis group (P = 0.007 based on Kruskal-Wallis tests) (Fig. 3). Specifically, pro-C3 was highest in advanced fibrosis (median [IQR]: 29.8 ng/mL [26.9, 35.0]) compared with none/mild fibrosis (19.3 ng/mL [15.6, 24.7]; P = 0.001) and healthy participants (19.0 ng/mL [13.8, 26.0]) in pairwise comparisons using Dunn’s test. In multivariable-adjusted linear regression models, these differences were attenuated, but remained significant after adjusting for age, sex, and BMI z-score in model 1. When we added CTX-I (in model 2) or N-MID (in model 3) as covariates in linear regression models, differences in pro-C3 were only significant for comparisons of participants with NAFLD and advanced fibrosis versus healthy controls, but were attenuated for comparisons of participants with NAFLD and advanced versus NAFLD and none/mild fibrosis (Table 4).

pro-C3 levels according to other liver fibrosis scores or other histopathological variables

We conducted a sensitivity analysis to examine differences in pro-C3 if we instead used the

TABLE 1. CHARACTERISTICS OF THE FULL SAMPLE AND STRATIFIED BY NAFLD GROUP

|                          | Full Sample (n = 153) | Healthy (n = 65) | NAFLD (n = 88) | PValue*  |
|--------------------------|-----------------------|-----------------|---------------|----------|
| Age (years), mean (SD)   | 13.1 (3.7)            | 12.0 (4.4)      | 13.9 (2.9)     | 0.012    |
| Age category, n (%)      |                       |                 |               |          |
| ≤10 years old            | 36 (23.5%)            | 20 (30.8%)      | 16 (18.2%)     | 0.056    |
| 11-14 years old          | 73 (47.7%)            | 24 (36.9%)      | 49 (55.7%)     |          |
| ≥15 years old            | 44 (28.8%)            | 21 (32.3%)      | 23 (26.1%)     |          |
| Male sex, n (%)          | 88 (57.5%)            | 25 (38.5%)      | 63 (71.6%)     | <0.001   |
| Race/ethnicity, n (%)    |                       |                 |               |          |
| Non-Hispanic White       | 44 (28.8%)            | 21 (32.3%)      | 23 (26.1%)     | <0.001   |
| Non-Hispanic Black       | 28 (18.3%)            | 22 (33.8%)      | 6 (6.8%)       |          |
| Hispanic                 | 77 (50.3%)            | 21 (32.3%)      | 56 (63.6%)     |          |
| Asian                    | 4 (2.6%)              | 1 (1.5%)        | 3 (3.4%)       |          |
| BMI z-score, mean (SD)   | 2.1 (1.4)             | 0.8 (1.1)       | 3.1 (0.6)      | <0.001   |
| BMI category, n (%)      |                       |                 |               |          |
| Normal weight            | 36 (23.5%)            | 36 (55.4%)      | 0 (0.0%)       | <0.001   |
| Overweight               | 9 (5.9%)              | 8 (12.3%)       | 1 (1.1%)       |          |
| Obesity                  | 108 (70.6%)           | 21 (32.3%)      | 87 (98.9%)     |          |
| CTX-I (ng/mL), median (IQR) | 1.2 (0.9, 1.7)   | 1.3 (1.0, 1.7)  | 1.2 (0.9, 1.6) | 0.492    |
| N-MID (ng/mL), median (IQR) | 56.2 (29,680.7) | 59.3 (31,951.1) | 55.5 (27,750.1) | 0.132    |
| ALT (U/L), median (IQR)  | 66.0 (19,101.8)       | 18.0 (15,220.0) | 90.5 (72,129.2) | <0.001   |
| AST (U/L), median (IQR)  | 33.0 (21,53.2)        | 18.5 (16.2,23.8)| 44.5 (34.0,80.0) | <0.001   |

*P values calculated by Kruskal-Wallis t-test for continuous variables and chi-square test for categorical variables.

†Eleven control participants were missing values for ALT and AST.
| Characteristic          | Full Sample (n = 153) | Healthy (n = 65) | NAFLD (n = 88) | Boys (n = 88) | Girls (n = 65) |
|-------------------------|-----------------------|------------------|---------------|---------------|----------------|
|                        | Median (IQR)          | Median (IQR)     | Median (IQR)  | Median (IQR)  | Median (IQR)   |
|                        | P         | P            | P       | P             | P             |
| Overall                | 19.6 (15.0, 25.9)     | —               | 20.6 (15.8, 25.9) | —            | 18.3 (13.7, 25.9) |
| Age category           |                       |                 |            |               |                |
| ≤ 10 years old         | 22.9 (18.1, 28.4)     | <0.001          | 25.9 (20.9, 28.4) | 0.001         | 24.6 (18.7, 27.8) |
| 11-14 years old        | 22.4 (18.3, 31.2)     | <0.001          | 22.7 (19.6, 28.2) | 0.004         | 19.4 (15.4, 30.1) |
| ≥ 15 years old         | 16.4 (13.0, 21.2)     | ref             | 18.1 (14.6, 22.8) | ref           | 13.8 (12.7, 18.5) |
| Race/ethnicity         |                       |                 |            |               |                |
| Non-Hispanic White     | 19.6 (14.2, 23.4)     | ref             | 21.0 (15.6, 24.8) | ref           | 19.9 (16.5, 22.2) |
| Non-Hispanic Black     | 18.8 (14.8, 32.4)     | 0.20            | 17.5 (15.4, 18.1) | 0.22          | 18.4 (12.9, 25.5) |
| Hispanic               | 19.7 (15.4, 25.0)     | 0.45            | 22.5 (16.0, 28.2) | 0.30          | 18.4 (13.3, 24.1) |
| BMI category           |                       |                 |            |               |                |
| Normal weight          | 20.6 [16.3, 31.6]     | ref             | —           | —             | 20.5 (17.8, 31.6) |
| Overweight/obesity     | 19.3 [14.8, 25.0]     | 0.25            | —           | —             | 21.1 (14.6, 31.3) |

*P values were estimated from Dunn's test comparing PRO-C3 for each category to a reference category (indicated by "ref"). Bold values indicate P < 0.05.
†There were no significant differences in PRO-C3 for participants with NAFLD versus healthy controls (P = 0.40) and for boys versus girls (P = 0.10). There were no significant differences in PRO-C3 for ≤ 10 years old versus 11-14 years old for the full sample or any subgroup.
‡Due to small sample size (n = 4), Asian race/ethnicity was excluded from pairwise comparisons.
§All participants with NAFLD were overweight or obese; therefore, no pairwise comparisons were performed.
NASH-CRN fibrosis scores to dichotomize participants (advanced fibrosis = scores ≥ 3; none/mild fibrosis = scores ≤ 2). Most participants were dichotomized into the same category as with Ishak scores, except for 2 participants who were no longer categorized as having advanced fibrosis based on NASH-CRN scores. As shown in Supporting Fig. S1, PRO-C3 still differed significantly by fibrosis group in unadjusted analyses ($P = 0.043$ based on Kruskal-Wallis tests), such that PRO-C3 was highest in advanced fibrosis (median [IQR]: 28.3 [24.4, 32.4] ng/mL) compared with none/mild fibrosis (19.5 [15.6, 24.9] ng/mL; $P = 0.018$) and healthy participants (19.0 [13.8, 26.0] ng/mL; $P = 0.012$). Results were also similar in stepwise linear regression models when using NASH-CRN scores compared with the Ishak scores, except differences between participants with advanced fibrosis versus none/mild fibrosis were slightly attenuated (Supporting Table S2).

In an exploratory analysis, we also examined whether PRO-C3 varied according to other histology scores assessed by liver biopsy. As shown in Fig. 4, PRO-C3 did not differ according to grade of steatosis ($P = 0.90$), lobular inflammation ($P = 0.86$), portal inflammation ($P = 0.20$), or hepatocyte ballooning ($P = 0.64$) based on Kruskal-Wallis tests. Medians and IQRs for PRO-C3 according to each histological variable are given in Supporting Table S3.

**Discussion**

In this study, we measured PRO-C3, the N-terminal propeptide of type III procollagen that detects formation of type III collagen, in children with and without biopsy-proven NAFLD and across a range of ages and race/ethnicities. Our main finding was that PRO-C3 levels in childhood are strongly associated with age, whereby levels were highest in participants ages ≤ 10 years old and 11-14 years old, and then declined among older adolescents 15 years or older (approximately aligning with the end of the pubertal growth spurt). Consistent with a link between PRO-C3 levels and pubertal growth, we found that PRO-C3 was strongly and positive correlated both with CTX-I and N-MID, which are markers of bone remodeling that likely reflect tissue turnover during growth, so-called modeling. As a potential biomarker of advanced fibrosis in pediatric NAFLD, PRO-C3 was considerably higher in children with NAFLD and
advanced fibrosis (based on Ishak scores) compared to those with NAFLD and none/mild fibrosis or healthy children; however, these differences were weakened after adjusting for these bone biomarkers. This suggests that, although in adults PRO-C3 is considered to be a marker of active fibrogenesis,\(^{10,11,12,14}\) growth spurts confound the interpretation of PRO-C3 levels in children. Therefore, PRO-C3 may have limited utility as a diagnostic tool for advanced fibrosis in pediatric NAFLD until later adolescence. Because all of the participants with NAFLD and advanced fibrosis were under 15 years old in the present study, we could not test this hypothesis using a stratified analysis; therefore, future studies with larger sample sizes and a wider age range are needed to compare the utility of PRO-C3 as a biomarker of advanced fibrosis across different pubertal stages.

Remodeling of the ECM is a critical biological process throughout life for maintaining healthy tissue, but can become disturbed in certain disease states, including fibrosis; thus, ECM biomarkers have gained in interest as potential biomarkers of fibrogenesis in adults.\(^{11}\) However, increased tissue turnover skewed toward tissue build-up also occurs during periods of growth and hormonal changes, which represents a critical confounder in the relationship between ECM-related biomarkers and fibrosis in certain subgroups, especially youth. Studies both in mice\(^ {30}\) and in humans\(^ {31}\) have shown that biomarkers of type III procollagen vary with age, such that levels are

**FIG. 2.** Scatter plots showing correlations between PRO-C3 and the bone biomarkers CTX-I (A) and N-MID (B) among participants with NAFLD (n = 88) and healthy participants (n = 65). Correlation coefficients and P values were calculated by Spearman correlation. All trend lines were estimated by linear regression (method = "lm") in ggplot2.
constant during early childhood, with a peak during puberty, and then gradually fall into late adolescence/adulthood. In addition, Kehlet et al. described changes in collagen turnover biomarkers in 617 healthy adults, and PRO-C3 levels increased among post-menopausal women (> 60 years old) compared with men,(32) which suggests a potential impact of hormonal status on ECM remodeling; however, it should be noted that this study did not adjust for potential confounding variables, such as weight changes. In the present study, we confirmed several of these findings in a diverse sample of children with and without NAFLD, and expanded on this research by showing a strong relationship between trends in PRO-C3 and levels of bone resorption biomarkers, CTX-I and N-MID.

Regarding the utility of PRO-C3 as a biomarker for advanced fibrosis in pediatric NAFLD, we did observe higher PRO-C3 in participants with advanced fibrosis in analyses adjusting for age, sex, and BMI z-score, which aligns with studies in adults showing that PRO-C3 is an independent predictor of fibrosis stage in patients with NAFLD,(10) as well as other liver diseases including hepatitis B and C. (33,34) In fact, the median values that we observed for PRO-C3 in children with NAFLD and advanced fibrosis (29.8 ng/mL) and none/mild fibrosis (19.3 ng/mL) were similar to values reported in adults with NAFLD (31.7 and 17.9 ng/mL, respectively(10)). We cannot comment on longitudinal changes in PRO-C3 in this cohort, but findings from adult studies suggest that PRO-C3 has promise as a biomarker both for identifying patients with fibrotic liver disease at baseline, who may benefit the most from antifibrotic therapy, as well as for measuring improvements in liver fibrosis in response to treatment.(15,35) The utility of PRO-C3 as a response biomarker in pediatric NAFLD will need to be evaluated in future studies.

However, it is critical to note that these differences in PRO-C3 between participants with advanced versus none/mild fibrosis were considerably weakened when adjusting for either of the bone remodeling biomarkers CTX-I and N-MID. Therefore, caution should be exercised in using PRO-C3 as a fibrosis biomarker in youth with NAFLD before the pubertal growth spurt is complete. Relative to the literature, studies testing other noninvasive fibrosis prediction scores in pediatric NAFLD have also been largely unsuccessful,(8,36) and this may relate to confounding factors that are specific to childhood, such as the substantial growth that occurs, and differences in the

| TABLE 3. CHARACTERISTICS OF THE SAMPLE ACCORDING TO FIBROSIS STAGE BASED ON ISHAK SCORING |
|---------------------------------------------------------------|
| Advanced Fibrosis* (n = 8) | None/Mild Fibrosis* (n = 80) | Healthy (n = 65) | P† |
| Age (years), mean (SD) | 11.4 (2.2) | 14.2 (2.9) | 12.0 (4.4) | 0.002 |
| Male sex, n (%) | 6 (75.0%) | 57 (71.2%) | 25 (38.5%) | <0.001 |
| BMI z-score, mean (SD) | 2.9 (0.5) | 3.1 (0.6) | 0.8 (1.1) | <0.001 |
| Race/ethnicity, n (%) | | | | |
| White | 1 (12.5%) | 22 (27.5%) | 21 (32.3%) | <0.001 |
| Black | 0 (0.0%) | 6 (7.5%) | 22 (33.8%) | <0.001 |
| Hispanic | 7 (87.5%) | 49 (61.2%) | 21 (32.3%) | <0.001 |
| Asian | 0 (0.0%) | 3 (3.8%) | 1 (1.5%) | <0.001 |
| BMI category, n (%) | | | | |
| Normal weight | 0 (0.0%) | 0 (0.0%) | 36 (55.4%) | <0.001 |
| Overweight | 0 (0.0%) | 1 (1.2%) | 8 (12.3%) | <0.001 |
| Obesity | 8 (100.0%) | 79 (98.8%) | 21 (32.3%) | <0.001 |
| PRO-C3 (ng/mL), median (IQR) | 29.8 (26.9, 35.0) | 19.3 (15.6, 24.7) | 19.0 (13.8, 26.0) | 0.007 |
| CTX-I (ng/mL), median (IQR) | 1.7 (1.5, 2.1) | 1.2 (0.9, 1.6) | 1.3 (1.0, 1.7) | 0.019 |
| N-MID (ng/mL), median (IQR) | 73.7 (62.1, 102.2) | 52.1 (26.8, 71.8) | 59.3 (31.1, 95.1) | 0.019 |
| ALT (U/L), median (IQR)‡ | 188.0 (93.2, 316.5) | 89.5 (68.0, 122.2) | 18.0 (15.0, 22.0) | <0.001 |
| AST (U/L), median (IQR)‡ | 80.0 (53.2, 141.0) | 43.0 (33.5, 69.2) | 18.5 (16.2, 23.8) | <0.001 |

*Categorized based on Ishak scoring. Advanced fibrosis was defined by Ishak score ≥ 3.
†P-values calculated by Kruskal-Wallis t-test for continuous variables and chi-square test for categorical variables.
‡Eleven control participants were missing ALT and AST values.

constant during early childhood, with a peak during puberty, and then gradually fall into late adolescence/adulthood. In addition, Kehlet et al. described changes in collagen turnover biomarkers in 617 healthy adults, and PRO-C3 levels increased among post-menopausal women (> 60 years old) compared with men,(32) which suggests a potential impact of hormonal status on ECM remodeling; however, it should be noted that this study did not adjust for potential confounding variables, such as weight changes. In the present study, we confirmed several of these findings in a diverse sample of children with and without NAFLD, and expanded on this research by showing a strong relationship between trends in PRO-C3 and levels of bone resorption biomarkers, CTX-I and N-MID.

Regarding the utility of PRO-C3 as a biomarker for advanced fibrosis in pediatric NAFLD, we did observe higher PRO-C3 in participants with advanced fibrosis in analyses adjusting for age, sex, and BMI z-score, which aligns with studies in adults showing that PRO-C3 is an independent predictor of fibrosis stage in patients with NAFLD,(10) as well as other liver diseases including hepatitis B and C. (33,34) In fact, the median values that we observed for PRO-C3 in children with NAFLD and advanced fibrosis (29.8 ng/mL) and none/mild fibrosis (19.3 ng/mL) were similar to values reported in adults with NAFLD (31.7 and 17.9 ng/mL, respectively(10)). We cannot comment on longitudinal changes in PRO-C3 in this cohort, but findings from adult studies suggest that PRO-C3 has promise as a biomarker both for identifying patients with fibrotic liver disease at baseline, who may benefit the most from antifibrotic therapy, as well as for measuring improvements in liver fibrosis in response to treatment.(15,35) The utility of PRO-C3 as a response biomarker in pediatric NAFLD will need to be evaluated in future studies.

However, it is critical to note that these differences in PRO-C3 between participants with advanced versus none/mild fibrosis were considerably weakened when adjusting for either of the bone remodeling biomarkers CTX-I and N-MID. Therefore, caution should be exercised in using PRO-C3 as a fibrosis biomarker in youth with NAFLD before the pubertal growth spurt is complete. Relative to the literature, studies testing other noninvasive fibrosis prediction scores in pediatric NAFLD have also been largely unsuccessful,(8,36) and this may relate to confounding factors that are specific to childhood, such as the substantial growth that occurs, and differences in the
pathophysiology of NAFLD in children compared with adults. In particular, studies have shed light on the potential for more rapid progression of liver damage in children with NAFLD\(^3,4,37\) and have described an alternate histological pattern of NASH (type 2 or pediatric-type NASH), which is common in younger children and characterized by moderate-high steatosis with portal inflammation and fibrosis, but little or no ballooning.\(^38,39\) The exact mechanism to explain these differences in children versus adults remain unclear, but it may not be a coincidence that participants with advanced fibrosis in our pediatric NAFLD cohort tended to be younger than those with none/mild fibrosis, and may therefore reflect a unique population of children who develop progressive NAFLD at a young age, which will require different biomarkers than adults due to the simultaneous onset of the pubertal growth spurt.

**Fig. 3.** PRO-C3 levels according to fibrosis stage based on Ishak scores in children and adolescents with NAFLD and healthy controls. Participants were categorized with advanced fibrosis based on fibrosis scores ≥ 3 (n = 8) or none/mild fibrosis based on scores ≤ 2 (n = 80). \(P\) values were calculated for pairwise comparisons using the nonparametric Dunn’s test.

**Table 4. Estimates for PRO-C3 according to fibrosis stage based on Ishak scores in stepwise linear regression models**

| Model | Advanced Fibrosis* (n = 8) | None/Mild Fibrosis* (n = 80) | Healthy (n = 65) |
|-------|---------------------------|-------------------------------|-----------------|
| 1: Adjusted for age, sex, BMI z-score | Mean (95% CI)\(^\dagger\) | Mean (95% CI)\(^\dagger\) | Mean (95% CI)\(^\dagger\) |
| 2: Model 1 + CTX-I | 26.4 (20.5, 34.0) | 21.1 (19.1, 23.5) | 18.1 (16.0, 20.5) |
| 3: Model 1 + N-MID | 26.4 (20.9, 33.9) | 21.0 (19.0, 23.3) | 18.2 (16.1, 20.5) |

\(^\dagger\)Categorized based on Ishak scoring. Advanced fibrosis was defined by Ishak score ≥ 3.

\(^\dagger\)LS-means and 95% CIs estimated from multivariable-adjusted linear regression after back-transformation.

\(^\dagger\)\(P\) values estimated from pairwise comparisons of LS-means and 95% CIs for log-transformed PRO-C3 by fibrosis group, compared with advanced fibrosis as the reference category. Bold values indicate \(P < 0.05\).
As a proof-of-concept study, there are some limitations that should be noted. First, we are not able to state any causal relationship between PRO-C3 and other outcomes due to the cross-sectional design, and longitudinal, interventional studies will be needed to assess this. Second, our small sample size, and especially the limited number of children with advanced fibrosis in NAFLD, may affect our statistical power in detecting smaller effect sizes. Although we attempted to mitigate this by pooling several cohorts, the data from these cohorts were collected and stored over different time periods, which may have introduced additional variability in our estimates and CIs. We also could not definitively confirm that all healthy participants were without steatosis or fibrosis, because some were selected from previously completed studies that did not include MRI or liver biopsy assessments; however, we are sufficiently confident that the inclusion criteria for healthy participants limited this possibility. Furthermore, all participants with NAFLD had assessments of steatosis and fibrosis by liver biopsy; thus, this limitation did not affect comparisons within the NAFLD group. Finally, we did not have consistent assessments of pubertal stage on all participants, and therefore could not assess this variable as a covariate with PRO-C3, which would be needed to confirm potential confounding by the pubertal growth spurt. We also did not have assessments of other potential confounding variables, such as diabetes/prediabetes status, which may be relevant in the understanding of fibrogenesis in pediatric NAFLD. In addition, there were considerable differences in terms of demographics and other traits, such as adiposity measured by BMI z-score, between the participants with NAFLD and healthy participants. Although we attempted to control for this in analyses, it is possible that residual confounding was an issue.
In conclusion, we showed that, while PRO-C3 levels were considerably higher in children with NAFLD and advanced fibrosis, this relationship may be subject to the strong confounding effects of age and the pubertal growth spurt. Further validations studies in other pediatric cohorts with NAFLD, ideally with larger sample sizes and/or with longitudinal, repeated measurements of PRO-C3, will be needed in order to elucidate whether PRO-C3 may be a predictor of future fibrosis progression and/or of treatment response.

REFERENCES

1) Skinner AC, Perrin EM, Skelton JA. Prevalence of obesity and severe obesity in US children, 1999-2014. Obesity 2016;24:1116-1123.
2) Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015;10:e0169098.
3) Feldstein AE, Charatcharoenwitthaya P, Treeprasertkul S, Benson JT, Enders FB, Angulo P. The natural history of nonalcoholic fatty liver disease in children: follow-up study for up to 20 years. Gut 2009;58:1538-1544.
4) Cioffi C, Welsh J, Cleeton R, Caltharp S, Romero R, Wulkan M, et al. Natural history of NAFLD diagnosed in childhood: a single-center study. Children 2017;4:34.
5) Ekstedt M, Hagström H, Näs P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.
6) Hagström H, Näs P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-1273.
7) Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
8) Jackson JA, Konomi JV, Mendoza MV, Krasinskas A, Jin R, Caltharp S, et al. Performance of fibrosis prediction scores in pediatric non-alcoholic fatty liver disease. J Paediatri Child Health 2018;54:172-176.
9) Niemelä O, Risteli L, Parkkinen J, Risteli J. Collagen and tissue turnover as a function of age: biochemical markers of liver fibrosis. Liver Int 2020;134:105220.
10) Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 2019;69:1075-1086.
11) Karlsson MA, Daniels SJ, Holm Nielsen S, Bager C, Rasmussen DGK, Loomba R, et al. Collagen biology and non-invasive biomarkers of liver fibrosis. Liver Int 2020;40:736-750.
12) Bril F, Leeming DJ, Karlsson MA, Kalvalapalli S, Barb D, Lai J, et al. Use of plasma fragments of peptide types of PRO-C3, V, and VI procollagen for the detection of liver fibrosis in type 2 diabetes. Diabetes Care 2019;42:1348-1351.
13) Luo YI, Oseini A, Gagnon R, Charles ED, Sidik K, Vincent R, et al. An evaluation of the collagen fragments related to fibrogenesis and fibrolysis in nonalcoholic steatohepatitis. Sci Rep 2018;8:12414.
31) Trivedi P, Cheeseman P, Portmann B, Hegarty J, Mowat AP. Variation in serum type III procollagen peptide with age in healthy subjects and its comparative value in the assessment of disease activity in children and adults with chronic active hepatitis. Eur J Clin Invest 1985;15:69-74.

32) Kehlet SN, Willumsen N, Arnbrecht G, Dietzel R, Brix S, Henriksen K, et al. Age-related collagen turnover of the interstitial matrix and basement membrane: implications of age- and sex-dependent remodeling of the extracellular matrix. PLoS One 2018;13:e0194458.

33) Nielsen MJ, Karsdal MA, Kazankov K, Grønbæk H, Krag A, Leeming DJ, et al. Fibrosis is not just fibrosis—basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury. Aliment Pharmacol Ther 2016;44:1242-1252.

34) Nielsen MJ, Veidal SS, Karsdal MA, Ørsnes-Leeming DJ, Vainer B, Gardner S, et al. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int 2015;35:429-437.

35) Karsdal MA, Henriksen K, Nielsen MJ, Byrjalsen I, Leeming DJ, Gardner S, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol 2016;311:G1009-G1017.

36) Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015;60:1440-1447.

37) Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, et al. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity 2013;21:591-597.

38) Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005;42:641-649.

39) Carter-Kent C, Yerian LM, Brunt EM, Angulo P, Kohli R, Ling SC, et al. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009;50:1113-1120.

Author names in bold designate shared co-first authorship.

Supporting Information

Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1766/suppinfo.